KPV 10mg

KPV 10mg Overview

KPV 10 mg is a short tripeptide composed of the amino acids lysine, proline, and valine. It corresponds to amino acids 11–13 of alpha-melanocyte-stimulating hormone (α-MSH) and is studied primarily for its role in regulating inflammatory signaling without retaining all functions of the complete α-MSH peptide.

In laboratory and animal models, KPV 10mg has been investigated for its interaction with PepT1, a transporter found in intestinal epithelial and immune cells. Experimental studies examine how this transport pathway may influence NF-κB and MAP kinase signaling, pro-inflammatory cytokine activity, and cellular responses within intestinal research systems.

KPV is also studied in skin, epithelial-barrier, and microbial models. Early laboratory research has examined its activity involving Staphylococcus aureus y Candida albicans, although these findings remain preclinical and should not be interpreted as evidence of clinical effectiveness.

Structure

• Número CAS: 67727-97-3
• Fórmula molecular: C₁₆H₃₀N₄O₄
• Peso molecular (promedio): ≈ 342.43 g/mol
• Masa monoisotópica (exacta): ≈ 342.2267 Da
• Peptide Sequence: Lys–Pro–Val

Compuesto de origen: α-Melanocyte-Stimulating Hormone, amino-acid residues 11–13

Sinónimos

• KPV
• Lys–Pro–Val
• Lysyl-prolyl-valine
• L-Lysyl-L-prolyl-L-valine
• α-MSH 11–13
• MSH 11–13

Chemical identifiers and molecular specifications are listed by PubChem for MSH 11–13.

Research Areas for KPV 10mg:

• Intestinal epithelial and immune-cell signaling
• PepT1-mediated peptide-transport models
• NF-κB and MAP kinase pathway research
• Pro-inflammatory cytokine-response studies
• Intestinal barrier and colitis research models
• Skin and keratinocyte signaling
• Epithelial-barrier response studies
• Preliminary antimicrobial research

Resumen condensado de la investigación

KPV 10 mg is utilized as a compact research model for studying how α-MSH-derived peptide sequences influence inflammatory and epithelial signaling. Laboratory investigations focus on its transport through PepT1, its interaction with NF-κB and MAP kinase pathways, and its effects on cytokine activity in intestinal and immune-cell models.

Additional research examines KPV in skin, barrier-tissue, and microbial systems. Existing evidence is primarily based on in vitro and animal studies, and established human clinical evidence remains limited.

Nota solo para fines de investigación: KPV 10mg is not FDA-approved for therapeutic use; published findings are primarily preclinical and exploratory.